Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
26
0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
Labbafinejad Medical Center
Tehran, Tehran Province, Iran
Change in intraocular pressure
Time frame: 6 months
Change in extent of iris neovascularization
Time frame: 6 months
Best corrected visual acuity
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.